A Prospective Cohort Study on Colorectal Cancer Screening in Community Population
ConditionColorectal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorSinglera Genomics Inc.
About this trial
This study will validate the real world results of polygene methylation detection in colorectal cancer in a large prospective community cohort. In this study, questionnaire survey and polygene methylation detection technology of colorectal cancer were used as preliminary screening methods, and colonoscopy was used as further validation examination method to screen colorectal cancer and precancerous lesions. The diagnosis and outcome of all lesions were based on colonoscopy and pathological examination.
Eligibility criteria
Qualifiers
Chronological age ≥40 years;
Full capacity for action;
After enrollment, the participants were able to complete the Colorectal Cancer Risk Factor Assessment Questionnaire and the annual follow-up interviews;
In the course of the study, the information related to tumor diagnosis in other hospitals can be timely fed back to the researchers;
Disqualifiers
History of colorectal cancer and other malignant tumors;
Previous colorectal resection;
undergoing any cancer-related treatment;
Patients who have received major surgical treatment such as blood transfusion or transplantation within 3 months;
Trial design
Treatments tested in this trial
- Not listed
Trial groups
18,000 Participants
are grouped into 2 trial groupsSponsors and collaborators
Singlera Genomics Inc.
Lead sponsor
Peking University Shougang Hospital
Collaborator
Source ClinicalTrials.gov